This comprehensive financial analysis and valuation capstone features an advanced equity research dashboard evaluating the five-year historical performance (2020–2024) and three-year pro forma projections (2025E–2027E) of Netflix, benchmarked against key industry peers like The Walt Disney Company and Spotify. The project integrates an array of sophisticated financial frameworks, including vertical and horizontal common-size analysis, liquidity and leverage ratio metrics, and a multi-stage DuPont Analysis to dissect the core drivers of Return on Equity (ROE). It features a robust multi-period Discounted Cash Flow (DCF) model and Free Cash Flow to Firm (FCFF) valuation, complete with a two-dimensional sensitivity matrix assessing Enterprise Value against fluctuations in cost of capital (WACC) and terminal growth rates. To ensure reporting integrity and systemic risk evaluation, the project applies advanced diagnostic accounting modules, including the Beneish M-Score forensic model to detect earnings manipulation, a Cash Conversion Cycle (CCC) analysis to assess working capital efficiency, and a dedicated comparative accounting cross-check evaluating the quantitative impact of IFRS vs. US GAAP standards. This capstone effectively demonstrates mastery in corporate valuation, forensic financial analysis, strategic forecasting, and international accounting reconciliation.

This comprehensive corporate finance capstone delivers an advanced, comparative equity research dashboard evaluating the ten-year historical performance (2014–2024) and five-year pro forma projections (2025F–2029F) of global industry giants Adidas and Unilever. The project showcases mastery in cross-sector financial analysis, incorporating full three-statement financial modeling, liquidity and leverage metrics, and a comparative Cash Conversion Cycle (CCC) evaluation to assess working capital and operational efficiencies. It utilizes historical stock return data against market benchmarks (DAX40 and FTSE 100) to isolate beta trends, calculates a customized cost of debt and cost of equity via market-implied and CAPM structures, and builds a robust multi-period Free Cash Flow valuation. To provide a rigorous strategic risk assessment under macroeconomic uncertainty, the dashboard integrates a multi-variable Scenario Analysis module (covering Base, Best, and Worst-case operational pathways) alongside a two-dimensional Sensitivity Matrix that maps asset Enterprise Values against shifting discount rates (WACC) and terminal growth expectations. Additionally, it applies Modern Portfolio Theory (MPT) principles through a quantitative risk-return optimization engine to evaluate portfolio variance-covariance dynamics. This asset stands as a clear validation of core competencies in quantitative financial engineering, strategic forecasting, multi-scenario stress testing, and investment analysis.

This institutional-grade corporate finance project features a fully integrated financial model and valuation dashboard designed for a clinical-stage biopharmaceutical firm (Ticker: KYTX). Developed to evaluate firm value across complex regulatory lifecycles, the model projects multi-year performance against explicit milestones, including Phase 3 clinical trials, FDA review, commercial launch, and long-term product growth. It integrates historical market data to calculate risk metrics, derives a precise cost of capital via the Capital Asset Pricing Model (CAPM) and weighted structure allocations, and establishes intrinsic value through a multi-period Discounted Cash Flow (DCF) framework using Free Cash Flow to Firm (FCFF). To account for the high volatility inherent in biotech asset pipelines, the project concludes with a two-dimensional sensitivity analysis that stress-tests Enterprise Value against fluctuations in terminal growth and hurdle rates. This artifact demonstrates advanced competencies in three-statement modeling, cost of capital determination, asset lifecycle forecasting, and quantitative risk management.